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tional threshold of $50,000 per QALY,manipulationwas cost-effective compared to
NSAIDs (the least costly alternative) (ICER$25,123 per QALY). NSAIDs were most
likely cost-effective at a WTP of $24,000 per QALY whereas manipulation was
most likely cost-effective between $24,000 and $50,000 per QALY. Cyclooxege-
nase-2 selective inhibitors and exercise were subject to simple dominance. The
ICER for mobilization was $381,926 per QALY. Probabilistic sensitivity analyses
suggested a high level of decision uncertainty. CONCLUSIONS: Manipulation is
cost-effective compared to NSAIDs at a conventional threshold of $50,000 per
QALY. Under varying thresholds, NSAIDs are cost effective at $24,000 per QALY.
Wewill identify themain drivers of the uncertainty surrounding the decision about
which treatment to adopt in forthcoming analyses.
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OBJECTIVES: Rheumatoid arthritis (RA) is a chronic illness that implies high direct
and indirect costs for the health system, particularly when biological therapy is pre-
scribed. The aim of this study was to evaluate the cost-utility of etanercept, adali-
mumab and infliximab for the treatment of rheumatoid arthritis (RA) in Colombian
adult population. METHODS: A cost-utility analysis was performed from a Markov
modelusing3-monthcycles, assumingadult patientswithRA treated for thefirst time
with anti-TNF drugs, in combinationwithmethotrexate (MTX). The time horizonwas
2 years and we used the third party payer perspective. The model was built using
effectiveness, safety and utilitymeasures taken from international registers and clin-
ical trials. Costs were gathered locally and results are expressed in 2010 Colombian
pesos; utility wasmeasured in quality-adjusted life-years (QALY) derived fromACR50
response, compliances rates and adverse events incidence. Drug costs (fixed by regu-
lations fromMinistry of Social Protection) as well as treatment costs of moderate and
serious adverse eventsmainly tuberculosis, pneumonia and cancer included; finally a
univariate sensitivity analysis was carried out. RESULTS: QALY’s gainedwith etaner-
cept, adalimumab and infliximab were 1.4689, 1.4627 and 1.4340, respectively; and
mean estimated costs resulted in US$41, 050, US$43,175 and US$47,190, respectively.
Etanercept was the cost-saving strategy, with a cost-effectiveness ratio of US$27,945/
QALY vs. US$29,520/QALY and US$32,910/QALY in comparison to adalimumab and
infliximab, explained by providing a better safety profile, better adherence to treat-
ment and lower drug costs. The key variables in sensitivity analysis were: drug costs,
frequency of adverse events and compliance rates, and conclusions were unaffected,
even when using extreme values, supporting the robustness of the model.
CONCLUSIONS:TreatmentofRAwithetanerceptMTX is thedominant combination
in Colombia, against adalimumabMTX or infliximabMTX, by providing more
QALYs gained at lower cost.
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OBJECTIVES: To estimate the cost-effectiveness of Abatacept in combination with
Methotrexate (MTX) versus other biologic DMARDs in combination with MTX in
patients with moderate to severe active Rheumatoid Arthritis. METHODS: A se-
quences treatmentmodel was adapted for the representation of disability in terms
of HAQ Index on a 5 year horizon for a cohort of 1000 patients. Abatacept in com-
bination with MTX was compared with etanercept, rituximab, infliximab, adali-
mumab and tocilizumab, all of themassociatedwithMTX. Currency is expressed in
Peruvian soles (S/.) of 2010. RESULTS: The cost of treatment with Abatacept re-
sulted in S/. 169 263 and its effectiveness was found to be 1.96 QALY. Regarding
Etanercept, Adalimumab, Infliximab and Tocilizumab, Abatacept has shown to be
themost effective in terms of QALYs and the least expensive. Regarding Rituximab,
Abatacept has an incremental cost effectiveness ratio of S/. 75 493 perQALY gained.
CONCLUSIONS:According to thismodel and inputs, Abataceptwas found to be dom-
inant against Etanercept, Adalimumab, Infliximab y Tocilizumab, from the Health
Social Security (EsSalud) perspective for the treatment of moderate to severe active
Rheumatoid Arthritis in patients who have failed to MTX based treatment.
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OBJECTIVES: Denosumab has recently been approved in the United States for the
treatment of postmenopausal women with ostepoporosis. Denosumab, a twice
yearly 60mg injection, provides an opportunity to model the effect of improved
treatment persistence on outcomeswhen compared to the daily dosing required of
patients on 60mg raloxifene, also a second line osteoporotic therapy.METHODS: A
previously developed Markov model was used to simulate outcomes for post-
menopausal women aged 65 with a bone mineral density (BMD) of less than 2.5.
We assumed a 20-year time horizon and a managed care perspective. Modeled
health states included vertebral, hip, and wrist fractures. Disease progression pa-
rameterswere derived fromphase III clinical trials. Costswere obtained using large
epidemiologic studies. Quality-adjusted life-years (QALYS) were used to assess
outcomes, and utility weights were derived from recent systematic reviews detail-
ing utility values associated with various osteoporotic fracture states. RESULTS:
Denosumab is dominated by raloxifene, as indicated by higher costs and poorer
outcomes. Persistence rates associated with both treatments had the greatest im-
pact on resulting incremental cost-effectiveness ratios. Estimated 20-year aggre-
gated costs and QALYs per person using denosumab are $26,123 and 12.63, respec-
tively compared to $23,670 per person and 13.05 per person for raloxifene. The ICER
was most sensitive to changes in persistence rates. Raloxifene was universally
dominant under all one-way sensitivity analysis scenarios. CONCLUSIONS: Deno-
sumab is not cost-effective compared to raloxifene. Further research should assess
whether the costs associated with improved denosumab persistence are offset by
reduced fracture rates and costs of fracture treatment.
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OBJECTIVES: The objective of this research was to assess the cost-effectiveness of
Chondroitin Sulphate (CS) used as treatment of Osteoarthritis (OA) of the knee in
mexican patients from the Mexican Public Health Institution perspective.
METHODS:We developed a Markov analytical model for a cohort with 10 years to
assess costs and benefits associated with the use of CS in the treatment of OA in
Mexicans patients. Comparator for CS was normal care (gold standard treatment).
Effectiveness measure was QALYs. These values were estimated by literature re-
view validated by expert panel consensus. The direct costs, treatment of adverse
events and knee surgery in the treatment of OA were estimated. The unitary costs
were obtained from the Mexican public health institutions. All costs were calcu-
lated in 2010 Mexican Pesos (MXP). Incremental-cost-effectiveness-ratios were ex-
pressed as cost per quality-adjusted-life-year (QALY). Costs and QALYs were dis-
counted at 5%. Probabilistic sensitivity analyses via Monte Carlo simulations were
undertaken to incorporate likely distributional properties of key model
parameters. RESULTS: The QALYS increased with CS on 4.89 and with standard
treatment on 4.73. Total treatment to include CS costs increased $25,470.13 MXP,
resulting in an incremental cost per QALY in $158,587.77 MXP. This incremental
cost utility is less than 1 Mexican PIB per capita. Deterministic and probabilistic
sensitivity analyses showed the robustness of the results. CONCLUSIONS: CS is a
cost efficient and useful for the treatment of OA in public health systems
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OBJECTIVES: The relationship between out-of-pocket (OOP) healthcare costs with
productivity is not well known. This study explores the relationship of OOP health-
care costs on productivity.METHODS: Participants self-identifiedwith RA and aged
18 completed an internet-based cross-sectional survey in 1Q2009. Self-reported
productivity loss including absenteeism, presenteeism, overall work impairment
and activity impairment expressed as impairment percentages, weremeasured by
the Work Productivity and Activity Impairment questionnaire. Participants were
asked about RA-related and overall monthly OOP healthcare costs. Negative bino-
mial regressionmodelswere developed to adjust for age, gender, ethnicity, income,
education, andmarital status.RESULTS: 455 RApatients participated in the survey.
Average age was 52 years, 67% were female, 36% were employed, and 23% were on
short- or long-term disability. More than half (53%) reported annual household
incomes between $50-100K, and 30% were college educated. Overall monthly OOP
costs were: $0-$50 for 54.1%, $51-$100 for 19.3%, $101-$200 for 15.8%, and$200 for
10.8%. Among employed patients, the rates of absenteeism, presenteeism, and
overall work impairment were 13.7%, 23.7% and 28.9%, respectively. Both em-
ployed and unemployed patients reported 58.4% impairment in daily activities.
Significantly greater productivity loss (presenteeism, b  1.01, p  0.038) and ac-
tivity impairment (b  0.21, p  0.006) were observed among patients with overall
OOP costs $200, and significantly greater activity impairment was observed
among theOOP costs category of $101-200 (b 0.15, p 0.026) as compared to those
with OOP costs between $0-50 after adjusting for patient demographics.
CONCLUSIONS: Higher monthly OOP costs were associated with higher activity
impairment and lower productivity; however, due to cross-sectional study design,
direction of associations cannot be determined. Shifting healthcare costs to em-
ployees may be associated with productivity loss. Further research is needed to
determine long-term impact of OOP healthcare costs on work productivity.
Muscular-Skeletal Disorders – Patient-Reported Outcomes & Preference-Based
Studies
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OBJECTIVES: No head-to-head clinical trial has compared the efficacy of adali-
mumab versus etanercept as first-line therapy for patients with psoriatic arthritis
(PsA). To bridge this gap, we implemented a matching-adjusted indirect compari-
son of adalimumab versus etanercept for PsA.METHODS: Using methodology de-
veloped by Signorovitch, patient-level data from the adalimumab randomized con-
trolled trial (RCT) ADEPT were reweighted to match baseline characteristics from
the pivotal published etanercept RCT. ADEPT patients were reweighted by their
odds of enrollment in the etanercept trial, estimated using logistic regression
model. Matched characteristics included demographics, baseline clinical mea-
sures, and concomitant treatment. After matching, biologic treatment arms were
compared based on difference from placebo in percent achieving 20%, 50%, or
70% improvement in ACR criteria (ACR20/50/70), percent meeting PsA Response
Criteria (PsARC), mean change in Health Assessment Questionnaire (HAQ), percent
with 50%, 75%, or 90% improvement in PASI (PASI50/75/90), and change from
baseline inmodified total Sharp score (mTSS). Statistical significance was assessed
using weighted Student’s t-tests. RESULTS: After reweighting, baseline character-
istics were exactly matched across trials. Compared with etanercept-treated pa-
tients, adalimumab-treated patients had greater placebo-adjusted rates of ACR70
(23.9% vs. 7.9%), PASI50 (60.5% vs. 29.2%), PASI75 (55.0% vs. 19.5%), and PASI90
(40.2% vs. 2.8%) at Week 24 (all p0.05). Adalimumab-treated patients also had
greater change frombaseline vs. placebo inmTSS (1.77 vs. 0.56, p0.080) atWeek 24
and greater rate of ACR70 (20.6% vs. 9.7%, p0.055) at Week 12. No significant
differences were found for ACR20, ACR50, PsARC, and HAQ change (all p0.1).
CONCLUSIONS: Matching-adjusted indirect comparison of adalimumab vs. etan-
ercept in PsA finds that adalimumab treatment is associated with greater proba-
bility of ACR70, PASI50, PASI75, and PASI90 at Week 24.
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OBJECTIVES: The objective of this study is to examine the impact of the doughnut
hole on medication behavior for biologic disease modifying anti-rheumatic drugs
(DMARDs) inMedicare beneficiaries that were diagnosedwith rheumatoid arthritis
(RA).METHODS: A retrospective cohort study was conducted using inpatient, out-
patient and pharmacy claims of a 5% national sample of Medicare beneficiaries
who were diagnosed with RA in 2007. Dual and non-dual eligible beneficiaries who
hit the doughnut hole were identified in order to test for differences in medication
behaviors among these groups. An independent samples t-test was carried out to
test for differences in adherence levels to biologic DMARDs and multiple logistic
regression analyses were carried out to test for differences in switching and dis-
continuation behaviors between the groups. Propensity scores were calculated to
control for demographic factors in the regression analyses. RESULTS: 86% of RA
beneficiaries hit the doughnut hole in 2007, with nearly 66% during the first three
months of the year. Adherence levels of non-dual eligibles were found to be signif-
icantly higher than those for dual-eligibles (p-value  0.001). Non-dual eligibles
were significantly more likely to switch their medication post doughnut hole as
compared to dual eligibles (OR  1.596, CI  1.132–2.249). Also, non-dual eligibles
were more likely to discontinue their medications post hitting the doughnut hole,
although their behavior was not found to be significantly different from the dual
eligibles (OR  1.418, CI  0.935–2.151). CONCLUSIONS:Medicare beneficiaries us-
ing specialty drugs may have to increasingly switch or discontinue their medica-
tions as a result of exceedingly high costs they incur in the doughnut hole. Biologic
DMARDs are required to inhibit progression of RA and thus, beneficiaries suffering
fromRA are not left withmuch of a choice but to incur these high costs if theywant
to successfully manage their disease.
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BACKGROUND: Adherence to osteoporosis medications is suboptimal with re-
ported persistence rates of between 25% and 35% at one year. This results in higher
fracture rates with significant medical costs and hospitalizations. OBJECTIVES: To
critically appraise the literature and determine the most effective adherence-en-
hancing interventions for osteoporosis medications. METHODS: A literature
search usingMedline, EMBASE, Cochrane library and CINAHLwas carried out using
the following keywords: osteoporosis, low bone density, low bonemineral density,
low bone mass, low bone mass density and bisphosphonates, calcium, colecalcif-
erol, estrogens, hormone replacement therapy (HRT), raloxifene, vitamin D and
patient compliance, adherence, concordance, persistence, and interventions, clin-
ical trials, RCT. The search period was January 1st, 1999 to July 31st, 2010. We in-
cluded studies on adult users of osteoporosis medications that tested an adher-
ence-enhancing intervention (e.g. patient education, intensified patient care), and
which reported quantitative results of adherence. Each article was reviewed inde-
pendently by two investigators and disagreements were resolved by consensus.
Downs’ checklist was modified to assess the quality of studies. Due to studies
heterogeneity, the analysis was focused on qualitative assessment. RESULTS: 27
publications were identified including 8 studies which randomized more than
4,500 patients fulfilled the inclusion criteria. Articles on reviews (5), protocols (1),
lack of intervention (7) or no quantitative data on adherence (6) were excluded. The
most frequent intervention was education (6) followed by monitoring/supervision
(2). Four studies used randomization to allocate intervention, which was led by
nurses (3), pharmacists (1), physicians (1) and multidisciplinary teams (2). Fol-
low-up ranged from 3 to 48 months. The average intervention effect size ranged
from 0.12 (education) to 0.24 (patients monitored by nursing staff). The average
quality score was 65.7%. CONCLUSIONS: Themost effective adherence-enhancing
interventions for osteoporosis medications were patient monitoring by nursing
staff and education. Future studies should assess adherence interventions based
on specific pharmacological treatments.
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OBJECTIVES: To determine preferences and marginal willingness to pay (MWTP)
for osteoarthritis (OA) treatments, including complementary and alternative med-
icine (CAM) among a sample of Medicare beneficiaries with mild and moderate-
severe OA.METHODS: A discrete choice conjoint analysis was conducted with 181
participants with OA recruited from 4 senior centers and one internal medicine
practice. Data were analyzed using Sawtooth Software. OA severity was deter-
mined by the brief pain inventory short form (BPI-sf), using previously established
cut points. Utility data and MWTP were derived from multinomial logit analysis.
This study was conducted in accordance with ISPOR’s Checklist for Good Research
Practices in Conjoint Analysis. RESULTS: Prescription pain medication, prayer/
spiritual healing, and over the counter (OTC) medications were the most preferred
treatments for both groups. The utility value for prescription pain medication was
.28 for mild OA and .56 for moderate-severe OA participants. Prayer was the most
preferred CAM treatment with significant utility values of .69 and .78 for mild and
moderate-severe OA participants, respectively. OTC medications had a significant
utility value of .39 for mild OA and .24 for moderate-severe OA participants. Signif-
icant differences were that moderate-severe OA participantshad strong prefer-
ences for acupuncture (.94) and mild OA participants had significant preferences
for massage therapy (.28). The price attribute followed the expected trend as lower
prices were associated with higher utility, although moderate-severe OA partici-
pants were less price sensitive and were willing to pay more for treatment than
mild OA participants. CONCLUSIONS: As OA severity increases, patients become
less price-sensitive. Additionally, OA patients have significant preference for CAM
in addition to conventional treatments. These data suggest that healthcare provid-
ers should involve patients in treatment decisions to optimize treatment accep-
tance and compliance. As options for CAM alone and in conjunction with conven-
tional medications become increasingly available, the relationship between
patient preferences and health outcomes is important to examine.
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BACKGROUND:Gout is themost common inflammatory arthritis inmen above age
40 and its prevalence is rapidly rising. However, the burden of this disease on
health-related quality of life (HRQOL), productivity and healthcare resource utili-
zation from a patient’s perspective has not been well published. OBJECTIVES: To
explore the self-reported gout burden on HRQOL of gout patients (N1468), their
resource utilization, and general health compared to an age/gendermatched gout-
free group controls (N1468). METHODS: Data were obtained from the 2010 US
National Health and Wellness Survey, an annual internet-based survey of nation-
ally representative adults. Respondents reported their health conditions, HRQOL
using SF-12, work and activity impairment (past week), and resource utilization
(past six months). These patients were then compared to an age and gender
matched gout-free cohort using 2-sided t-test or Chi Square test, p 0.05 indicating
statistical significance. RESULTS: The prevalence of self-reported gout in this sur-
veywas 1.9%. 78% of these patientsweremalewith amean age of 60 years, and BMI
of 32.7. 88% were physician diagnosed and 69% were treated with gout-specific
medication. There was no difference in alcohol use between 2 cohorts. The gout
patients however, had significantly higher comorbidity rate for hypertension, hy-
perlipidemia, diabetes, and CHF, 3x rate of Myocardial Infarction, and 4x rate of
moderate/severe renal disease (p 0.05 for all). They had lower SF-12 domain
scores, physical and mental summary scores than gout-free controls (p 0.05).
Fewer gout patientswere employed full time, and larger numberwere on long-term
disability (p 0.05). They had twice the amount of work and social impairment,
double thenumber of ERvisits, hospitalizations, andmeanvisits to varioushealthcare
providers (p 0.05 for all). CONCLUSIONS: Gout patients have significantly lower
HRQOL, larger burden of work and activity impairment, and greater resource utiliza-
tion than gout-free controls.
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OBJECTIVES: In the context of a French national post-marketing study on patients’
satisfaction with routine care management, decision was made to use the Patient
Satisfaction Questionnaire (PSQ III). Developed in the USA, the PSQ-III contains 8
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